Note: Ingredients listed on restricted chemical lists
EC/CAS
9003-39-8
Name of the chemical
polyvinylpyrrolidone
Concentration
N/A
EC/CAS
25655-41-8
Name of the chemical
Polyvinylpyrrolidone iodine
Concentration
N/A
EC/CAS
9005-65-6
Name of the chemical
polyethyleneglycol sorbitan monooleate
Concentration
N/A
General Information
Version
2.0
Revision date
2022-04-20
Product name
Raloxifene Hydrochloride Tablet USP, 60 mg
Icons in SDS
Company Information
company name
Cadila Pharmaceuticals Limited
Section 2
SECTION 2: Hazards identification
OSHA Not considered hazardous when handled under normal conditions. EMERGENCY OVERVIEW • Caution Statement: Intact Raloxifene Hydrochloride Tablets, USP are not considered to be a health hazard. Effects of exposure to contents may cause skin irritation, Highly Potent and Reproductive Hazard.
Principle Routes of Exposure
oral Effects of overexposure: tablets are intended for human consumption under guidance of a physician. Intact tablets are not considered hazardous under normal handling procedures.
Medical Conditions Generally Aggravated by Exposure
Hypersensitivity to material; active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis; heart problems; neoplasms; impaired liver or kidney function; and undiagnosed uterine bleeding. Carcinogenicity Raloxifene hydrochloride - Not listed by IARC NTP and
